Darunavir - Janssen R&D Ireland

Drug Profile

Darunavir - Janssen R&D Ireland

Alternative Names: Prezista; TMC-114; Virem

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland
  • Class Antiretrovirals; Sulfonamides
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections; HIV-1 infections

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 23 Nov 2017 Janssen R&D Ireland completes a continued access phase II trial in HIV-1 infections (Combination therapy, In Children In adolescents, In adults, In the elderly) in Argentina, Brazil, France, India, South Africa, Spain, Ukraine, United Kingdom and Italy (PO) (NCT01138605) (EudraCT2009-017013-29)
  • 01 Feb 2017 Janssen completes a phase III trial in HIV-1 infections (Combination therapy, Treatment-experienced, Monotherapy) in Cameroon, Burkina Faso, Senegal (PO) (NCT01905059)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top